News
-
-
-
PRESS RELEASE
rapport financier semestriel
-
PRESS RELEASE
Formycon and Fresenius Kabi receive European Commission approval for FYB202/Otulfi® (ustekinumab) for the treatment of serious inflammatory diseases
Formycon and Fresenius Kabi secure European Commission approval for FYB202/Otulfi® (ustekinumab) to treat inflammatory diseases, expanding biosimilar portfolio -
-
-
PRESS RELEASE
Supervisory Board of Mutares extends CEO Robin Laik's Management Board contract prematurely by a further five years
Supervisory Board of Mutares extends CEO Robin Laik's Management Board contract by five years until 2029. CEO Laik and his team continue to drive growth and expansion of Mutares SE & Co. KGaA -
-
-